Your browser is no longer supported. Please, upgrade your browser.
Settings
TCON TRACON Pharmaceuticals, Inc. daily Stock Chart
TCON [NASD]
TRACON Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own1.50% Shs Outstand10.51M Perf Week22.15%
Market Cap126.31M Forward P/E- EPS next Y-1.39 Insider Trans- Shs Float9.18M Perf Month91.18%
Income-16.40M PEG- EPS next Q-0.32 Inst Own42.60% Short Float2.34% Perf Quarter432.16%
Sales- P/S- EPS this Y42.40% Inst Trans239.84% Short Ratio0.16 Perf Half Y295.65%
Book/sh1.47 P/B6.19 EPS next Y26.50% ROA-84.60% Target Price7.50 Perf Year166.86%
Cash/sh- P/C- EPS next 5Y- ROE-273.70% 52W Range0.95 - 10.11 Perf YTD288.89%
Dividend- P/FCF- EPS past 5Y-4.90% ROI- 52W High-9.97% Beta1.71
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low857.89% ATR0.85
Employees19 Current Ratio2.80 Sales Q/Q- Oper. Margin- RSI (14)71.10 Volatility15.08% 12.96%
OptionableNo Debt/Eq0.30 EPS Q/Q78.10% Profit Margin- Rel Volume0.61 Prev Close8.44
ShortableYes LT Debt/Eq0.14 EarningsNov 10 AMC Payout- Avg Volume1.37M Price9.10
Recom2.20 SMA2040.23% SMA5060.96% SMA200202.34% Volume838,901 Change7.82%
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Feb-24-15Initiated Stifel Buy $16
Feb-24-15Initiated Oppenheimer Outperform $22
Nov-23-20 08:05AM  
Nov-16-20 09:45AM  
Nov-10-20 04:03PM  
02:45PM  
Nov-03-20 08:05AM  
Oct-26-20 08:05AM  
Sep-25-20 11:29AM  
Sep-21-20 08:05AM  
Sep-10-20 08:05AM  
Sep-09-20 11:51AM  
Sep-03-20 08:05AM  
Aug-31-20 08:05AM  
Aug-27-20 08:05AM  
Aug-25-20 11:49AM  
Aug-24-20 11:59AM  
Aug-17-20 11:08AM  
08:38AM  
08:05AM  
Aug-05-20 04:05PM  
Aug-03-20 08:05AM  
Jul-29-20 04:05PM  
Jul-16-20 08:15AM  
Jul-13-20 08:15AM  
Jun-22-20 02:19PM  
Jun-11-20 10:56PM  
Jun-05-20 02:48PM  
Jun-01-20 08:05AM  
May-29-20 08:20AM  
May-14-20 08:32AM  
May-13-20 04:04PM  
May-11-20 08:15AM  
May-06-20 04:05PM  
Apr-24-20 08:15AM  
Apr-14-20 08:15AM  
Apr-06-20 08:15AM  
Mar-19-20 08:15AM  
Mar-18-20 03:29AM  
Mar-16-20 08:15AM  
Mar-09-20 07:40PM  
Feb-28-20 07:28AM  
Feb-27-20 04:03PM  
Feb-20-20 06:00PM  
Feb-07-20 08:05AM  
Jan-20-20 01:14PM  
Dec-22-19 05:10PM  
Dec-20-19 08:58AM  
07:00AM  
Nov-21-19 09:37PM  
Nov-08-19 08:05AM  
Nov-05-19 04:05PM  
Oct-29-19 04:15PM  
Oct-21-19 08:05AM  
Oct-07-19 12:40PM  
Sep-03-19 08:05AM  
Aug-29-19 08:05AM  
Aug-28-19 08:05AM  
Aug-07-19 04:02PM  
08:05AM  
Aug-01-19 11:33AM  
08:05AM  
Jul-31-19 04:05PM  
Jul-29-19 08:05AM  
Jul-02-19 08:05AM  
Jun-27-19 11:40AM  
Jun-07-19 01:23PM  
May-30-19 08:05AM  
May-15-19 01:31PM  
May-14-19 06:57PM  
04:03PM  
02:30PM  
May-07-19 04:05PM  
Apr-12-19 10:45AM  
07:11AM  
06:55AM  
Mar-27-19 08:05AM  
Mar-07-19 01:08PM  
Mar-01-19 02:30PM  
Feb-28-19 04:02PM  
02:30PM  
Feb-21-19 04:03PM  
Jan-22-19 08:30AM  
Dec-31-18 07:35AM  
Dec-27-18 08:35AM  
07:51AM  
Dec-26-18 04:05PM  
08:35AM  
Dec-21-18 08:10AM  
Dec-04-18 07:00PM  
Dec-03-18 08:35AM  
Nov-29-18 02:01AM  
Nov-19-18 08:35AM  
Nov-15-18 08:35AM  
Nov-14-18 09:04AM  
Nov-13-18 08:20AM  
Nov-08-18 12:58PM  
Nov-07-18 06:54PM  
04:02PM  
07:50AM  
Oct-31-18 04:02PM  
Oct-15-18 01:00PM  
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ikarian Capital, LLCMember of 10% GroupNov 11Buy7.535,00037,6292,196,549Nov 12 06:18 PM
Ikarian Capital, LLCMember of 10% GroupOct 30Buy4.6421,30098,9072,191,549Nov 12 06:18 PM
Ikarian Capital, LLCMember of 10% GroupOct 29Buy4.777,70036,7342,170,249Nov 12 06:18 PM
THEUER CHARLESPresident and CEOOct 21Buy4.382,0008,769189,232Oct 23 06:00 AM
Opaleye Management Inc.10% OwnerOct 21Buy4.408,65638,0601,797,094Oct 23 09:30 PM
Opaleye Management Inc.10% OwnerSep 24Buy4.4421,53495,6481,785,438Sep 25 09:30 PM
Opaleye Management Inc.10% OwnerSep 23Buy4.8357,200276,4481,764,438Sep 25 09:30 PM
THEUER CHARLESPresident and CEOSep 23Buy4.725,00023,599186,882Sep 25 06:00 AM
Ikarian Capital, LLCMember of 10% GroupSep 11Buy3.9378,201307,0172,162,549Sep 15 09:19 PM
WIGGINS MARK CChief Business OfficerSep 10Buy4.147,00028,95312,350Sep 14 01:49 PM
Opaleye Management Inc.10% OwnerSep 09Buy3.4747,500164,7731,709,438Sep 09 06:15 PM
Ikarian Capital, LLCMember of 10% GroupSep 09Buy3.4979,415277,4602,084,348Sep 15 09:19 PM
Ikarian Capital, LLCMember of 10% GroupSep 08Buy2.9013,24438,4082,004,933Sep 15 09:19 PM
Ikarian Capital, LLCMember of 10% GroupSep 04Buy2.87151,611434,5021,991,689Sep 15 09:19 PM
Opaleye Management Inc.10% OwnerSep 04Buy2.889,05826,1301,664,438Sep 09 06:15 PM
THEUER CHARLESPresident and CEOSep 04Buy2.5810,00025,750181,882Sep 09 06:00 AM
Opaleye Management Inc.10% OwnerSep 02Buy2.35119,800282,0571,655,946Sep 03 05:15 PM
Opaleye Management Inc.10% OwnerSep 01Buy2.0440,00081,7681,540,946Sep 03 05:15 PM
Opaleye Management Inc.10% OwnerAug 31Buy1.76302,150530,4551,502,346Aug 31 09:36 PM
Opaleye Management Inc.10% OwnerAug 28Buy1.7860,000106,974210,000Aug 31 09:36 PM
Opaleye Management Inc.10% OwnerAug 27Buy1.71183,354312,9491,206,196Aug 31 09:36 PM
THEUER CHARLESPresident and CEOAug 21Buy1.565,3258,307171,882Aug 25 06:00 AM
THEUER CHARLESPresident and CEOAug 20Buy1.5830,00047,400166,557Aug 24 06:06 AM
THEUER CHARLESPresident and CEOAug 18Buy1.6344,74372,851136,557Aug 18 08:28 PM
THEUER CHARLESPresident and CEOAug 14Buy1.7010017091,814Aug 18 08:28 PM
THEUER CHARLESPresident and CEOAug 13Buy1.655,0008,25091,714Aug 14 08:17 PM
THEUER CHARLESPresident and CEOAug 12Buy1.7515,00026,25086,714Aug 14 08:17 PM
THEUER CHARLESPresident and CEOJun 24Buy1.909,89518,80171,714Jun 25 05:46 PM
PELLETIER SAUNDRA LDirectorJun 15Buy2.073,0006,2095,500Jun 16 05:24 PM
PELLETIER SAUNDRA LDirectorJun 11Buy2.002,5005,0002,500Jun 16 05:24 PM
THEUER CHARLESPresident and CEOMay 22Buy1.9010,59220,11961,819May 26 05:00 PM
THEUER CHARLESPresident and CEOMar 13Buy1.134,1004,62450,877Mar 13 06:21 PM
THEUER CHARLESPresident and CEOMar 12Buy1.1810,00011,80346,777Mar 12 04:32 PM
THEUER CHARLESPresident and CEOMar 11Buy1.6810,00016,83736,777Mar 12 04:32 PM
THEUER CHARLESPresident and CEOMar 10Buy1.8710,00018,69126,777Mar 10 06:02 PM
WIGGINS MARK CChief Business OfficerJan 23Buy4.025,00020,1035,000Jan 24 04:10 PM
Puissance Cross-Border Opportu10% OwnerDec 09Sale2.92340,134993,19176,048Dec 11 10:47 AM
MRNA Moderna, Inc. daily Stock Chart
MRNA [NASD]
Moderna, Inc.
Index- P/E- EPS (ttm)-1.62 Insider Own2.40% Shs Outstand394.68M Perf Week22.83%
Market Cap41.06B Forward P/E25.11 EPS next Y4.35 Insider Trans-23.04% Shs Float355.95M Perf Month54.49%
Income-597.70M PEG- EPS next Q-0.62 Inst Own52.10% Short Float7.09% Perf Quarter60.49%
Sales246.70M P/S166.44 EPS this Y-27.10% Inst Trans-6.40% Short Ratio2.28 Perf Half Y77.53%
Book/sh6.99 P/B15.62 EPS next Y345.80% ROA-20.30% Target Price107.07 Perf Year437.04%
Cash/sh8.71 P/C12.53 EPS next 5Y16.80% ROE-28.10% 52W Range17.68 - 103.20 Perf YTD458.18%
Dividend- P/FCF67.00 EPS past 5Y- ROI-44.90% 52W High5.79% Beta-
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low517.53% ATR5.78
Employees830 Current Ratio2.40 Sales Q/Q828.80% Oper. Margin- RSI (14)74.87 Volatility6.06% 6.38%
OptionableYes Debt/Eq0.04 EPS Q/Q-58.90% Profit Margin- Rel Volume2.31 Prev Close98.56
ShortableYes LT Debt/Eq0.04 EarningsOct 29 BMO Payout- Avg Volume11.07M Price109.18
Recom2.20 SMA2033.32% SMA5044.85% SMA20085.43% Volume25,850,692 Change10.78%
Nov-23-20Initiated Wells Fargo Equal Weight $92
Nov-17-20Downgrade BMO Capital Markets Outperform → Market Perform $109
Sep-08-20Downgrade SVB Leerink Mkt Perform → Underperform $58 → $41
Jul-23-20Initiated SVB Leerink Mkt Perform
Jul-20-20Downgrade JP Morgan Overweight → Neutral $89
Jul-13-20Initiated Jefferies Buy $90
Jun-30-20Initiated Argus Buy $80
Jun-08-20Initiated Barclays Overweight $68
Apr-30-20Initiated BMO Capital Markets Outperform $83
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $32
Dec-03-19Resumed BofA/Merrill Buy
Oct-25-19Initiated ROTH Capital Buy $24
Apr-05-19Initiated Chardan Capital Markets Buy $40
Nov-27-20 08:22AM  
07:03AM  
Nov-26-20 02:25PM  
09:28AM  
07:21AM  
07:18AM  
12:38AM  
Nov-25-20 05:30PM  
04:39PM  
04:32PM  
04:28PM  
04:17PM  
03:36PM  
03:14PM  
01:52PM  
12:48PM  
11:48AM  
10:35AM  
10:16AM  
10:08AM  
09:49AM  
09:29AM  
08:46AM  
08:40AM  
08:08AM  
08:00AM  
07:43AM  
07:21AM  
06:55AM  
06:49AM  
06:45AM  
06:09AM  
06:00AM  
Nov-24-20 05:35PM  
02:39PM  
01:36PM  
01:30PM  
12:10PM  
11:45AM  
11:27AM  
11:12AM  
10:53AM  
09:21AM  
08:10AM  
07:40AM  
07:27AM  
06:37AM  
04:57AM  
04:47AM  
01:07AM  
01:03AM  
Nov-23-20 06:05PM  
06:00PM  
05:00PM  
04:13PM  
04:08PM  
04:06PM  
02:02PM  
02:01PM  
12:49PM  
11:31AM  
11:12AM  
10:59AM  
10:59AM  
10:38AM  
10:24AM  
10:15AM  
09:57AM  
09:56AM  
09:48AM  
09:23AM  
08:48AM  
07:03AM  
05:40AM  
03:43AM  
02:44AM  
02:11AM  
12:33AM  
Nov-22-20 11:31AM  
09:31AM  
07:22AM  
06:59AM  
Nov-21-20 06:00PM  
05:30PM  
04:31PM  
02:30PM  
11:30AM  
10:06AM  
09:32AM  
09:22AM  
09:16AM  
08:50AM  
06:40AM  
06:37AM  
06:09AM  
Nov-20-20 04:39PM  
04:25PM  
04:15PM  
01:42PM  
01:39PM  
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoge StephenPresidentNov 24Sale97.935,000489,6461,734,597Nov 25 04:21 PM
Zaks Tal ZviChief Medical OfficerNov 23Option Exercise16.8415,000252,55015,000Nov 24 04:24 PM
Hoge StephenPresidentNov 23Option Exercise0.9910,0009,9001,754,597Nov 25 04:21 PM
Hoge StephenPresidentNov 23Sale100.5415,0001,508,0651,739,597Nov 25 04:21 PM
Zaks Tal ZviChief Medical OfficerNov 23Sale100.5315,0001,507,9630Nov 24 04:24 PM
Bancel StephaneChief Executive OfficerNov 20Sale95.1017,5141,665,581298,258Nov 24 04:11 PM
Bancel StephaneChief Executive OfficerNov 19Sale89.8010,000898,0007,664,880Nov 20 04:20 PM
Bancel StephaneChief Executive OfficerNov 18Sale93.879,000844,8306,574,868Nov 20 04:20 PM
Zaks Tal ZviChief Medical OfficerNov 16Option Exercise16.8415,000252,55015,000Nov 17 04:58 PM
Zaks Tal ZviChief Medical OfficerNov 16Sale96.9915,0001,454,8300Nov 17 04:58 PM
Hoge StephenPresidentNov 13Option Exercise0.9910,0009,9001,759,597Nov 16 04:15 PM
Bancel StephaneChief Executive OfficerNov 13Sale87.0011,046961,002309,304Nov 16 04:10 PM
Hoge StephenPresidentNov 13Sale87.0015,0001,305,0001,744,597Nov 16 04:15 PM
Bancel StephaneChief Executive OfficerNov 12Sale84.9910,000849,9007,674,880Nov 16 04:10 PM
Hoge StephenPresidentNov 12Sale86.305,000431,4751,749,597Nov 16 04:15 PM
Bancel StephaneChief Executive OfficerNov 11Sale77.059,000693,4506,584,868Nov 12 04:12 PM
Bancel StephaneChief Executive OfficerNov 10Sale80.007,718617,4409,069,330Nov 12 04:12 PM
Zaks Tal ZviChief Medical OfficerNov 09Option Exercise16.8415,000252,55015,000Nov 10 04:26 PM
Zaks Tal ZviChief Medical OfficerNov 09Sale77.9615,0001,169,3340Nov 10 04:26 PM
Bancel StephaneChief Executive OfficerNov 06Sale71.5011,046789,789320,350Nov 10 04:15 PM
Bancel StephaneChief Executive OfficerNov 05Sale71.0910,000710,9007,684,880Nov 06 04:03 PM
Bancel StephaneChief Executive OfficerNov 04Sale68.979,000620,7306,594,868Nov 06 04:03 PM
Hoge StephenPresidentNov 03Option Exercise0.9910,0009,9001,764,597Nov 04 04:44 PM
Hoge StephenPresidentNov 03Sale66.7510,000667,5001,754,597Nov 04 04:44 PM
Hoge StephenPresidentNov 02Option Exercise0.9910,0009,9001,764,597Nov 04 04:44 PM
Zaks Tal ZviChief Medical OfficerNov 02Option Exercise16.8415,000252,55015,000Nov 04 04:49 PM
Bancel StephaneChief Executive OfficerNov 02Sale68.028,893604,9029,077,048Nov 04 04:38 PM
Hoge StephenPresidentNov 02Sale68.0210,000680,2001,754,597Nov 04 04:44 PM
Zaks Tal ZviChief Medical OfficerNov 02Sale67.1715,0001,007,4970Nov 04 04:49 PM
Bancel StephaneChief Executive OfficerOct 30Sale68.3611,046755,133331,396Nov 02 04:41 PM
Bancel StephaneChief Executive OfficerOct 29Sale68.3910,000683,9007,694,880Oct 30 04:21 PM
Bancel StephaneChief Executive OfficerOct 28Sale68.759,000618,7506,604,868Oct 30 04:21 PM
Zaks Tal ZviChief Medical OfficerOct 26Option Exercise16.8415,000252,55015,000Oct 27 04:42 PM
Hoge StephenPresidentOct 26Sale69.995,000349,9501,754,597Oct 27 08:22 PM
Zaks Tal ZviChief Medical OfficerOct 26Sale70.0015,0001,050,0040Oct 27 04:42 PM
Hoge StephenPresidentOct 23Option Exercise0.9910,0009,9001,926,530Oct 27 08:22 PM
Hoge StephenPresidentOct 23Sale70.0215,0001,050,3281,911,530Oct 27 08:22 PM
Bancel StephaneChief Executive OfficerOct 23Sale70.0111,046773,358342,442Oct 27 04:38 PM
Bancel StephaneChief Executive OfficerOct 22Sale68.5810,000685,8007,704,880Oct 23 04:30 PM
HENDERSON LORI M.General Counsel and SecretaryOct 21Option Exercise14.8532,000475,20032,681Oct 23 04:32 PM
Bancel StephaneChief Executive OfficerOct 21Sale71.319,000641,7906,614,868Oct 23 04:30 PM
HENDERSON LORI M.General Counsel and SecretaryOct 21Sale70.1632,0002,245,158681Oct 23 04:32 PM
Bancel StephaneChief Executive OfficerOct 20Sale72.058,455609,1839,085,941Oct 21 04:04 PM
Zaks Tal ZviChief Medical OfficerOct 19Option Exercise16.8415,000252,55015,000Oct 20 05:26 PM
Zaks Tal ZviChief Medical OfficerOct 19Sale71.9415,0001,079,0250Oct 20 05:26 PM
Bancel StephaneChief Executive OfficerOct 16Sale75.0211,046828,618353,488Oct 20 05:24 PM
Bancel StephaneChief Executive OfficerOct 15Sale75.4810,000754,8007,714,880Oct 16 04:45 PM
Bancel StephaneChief Executive OfficerOct 14Sale79.819,000718,2906,624,868Oct 16 04:45 PM
Hoge StephenPresidentOct 13Option Exercise0.9910,0009,9001,931,530Oct 14 04:15 PM
Hoge StephenPresidentOct 13Sale76.6315,0001,149,4121,916,530Oct 14 04:15 PM
Zaks Tal ZviChief Medical OfficerOct 12Option Exercise16.8415,000252,55015,000Oct 13 05:56 PM
Bancel StephaneChief Executive OfficerOct 12Sale73.618,219605,0019,094,396Oct 13 04:13 PM
Zaks Tal ZviChief Medical OfficerOct 12Sale74.4715,0001,117,0490Oct 13 05:56 PM
Hoge StephenPresidentOct 12Sale74.465,000372,2761,921,530Oct 14 04:15 PM
Bancel StephaneChief Executive OfficerOct 09Sale72.9911,046806,259364,534Oct 13 04:13 PM
Bancel StephaneChief Executive OfficerOct 08Sale73.5010,000735,0007,724,880Oct 09 04:10 PM
Bancel StephaneChief Executive OfficerOct 07Sale71.239,000641,0706,634,868Oct 09 04:10 PM
Hoge StephenPresidentOct 05Option Exercise0.9910,0009,9001,936,530Oct 06 04:45 PM
Zaks Tal ZviChief Medical OfficerOct 05Option Exercise16.8415,000252,55015,000Oct 06 04:51 PM
Hoge StephenPresidentOct 05Sale69.5010,000695,0001,926,530Oct 06 04:45 PM
Zaks Tal ZviChief Medical OfficerOct 05Sale70.2415,0001,053,6450Oct 06 04:51 PM
Hoge StephenPresidentOct 02Option Exercise0.9910,0009,9001,936,530Oct 06 04:45 PM
Bancel StephaneChief Executive OfficerOct 02Sale70.6411,046780,251375,580Oct 06 04:36 PM
Hoge StephenPresidentOct 02Sale67.8610,000678,6001,926,530Oct 06 04:45 PM
Bancel StephaneChief Executive OfficerOct 01Sale69.5718,4811,285,7237,734,880Oct 02 04:52 PM
Bancel StephaneChief Executive OfficerSep 30Sale72.729,000654,4806,644,868Oct 02 04:52 PM
Zaks Tal ZviChief Medical OfficerSep 28Option Exercise19.8917,197342,13317,197Sep 29 04:20 PM
Zaks Tal ZviChief Medical OfficerSep 28Sale70.2817,1971,208,5490Sep 29 04:20 PM
Bancel StephaneChief Executive OfficerSep 25Sale68.4911,046756,519386,626Sep 29 04:18 PM
Bancel StephaneChief Executive OfficerSep 24Sale65.5010,000655,0007,744,880Sep 25 04:12 PM
Hoge StephenPresidentSep 24Sale65.195,000325,9501,926,530Sep 25 04:19 PM
Hoge StephenPresidentSep 23Option Exercise0.9910,0009,9001,946,530Sep 25 04:19 PM
Bancel StephaneChief Executive OfficerSep 23Sale67.999,000611,9106,654,868Sep 25 04:12 PM
Hoge StephenPresidentSep 23Sale67.2215,0001,008,3611,931,530Sep 25 04:19 PM
Zaks Tal ZviChief Medical OfficerSep 21Option Exercise20.0420,000400,80020,000Sep 22 05:11 PM
Zaks Tal ZviChief Medical OfficerSep 21Sale67.3020,0001,345,9530Sep 22 05:11 PM
Bancel StephaneChief Executive OfficerSep 21Sale68.568,587588,7259,111,096Sep 22 05:03 PM
Bancel StephaneChief Executive OfficerSep 18Sale67.7111,046747,901397,672Sep 22 05:03 PM
Bancel StephaneChief Executive OfficerSep 17Sale68.4610,000684,6007,754,880Sep 18 04:13 PM
Bancel StephaneChief Executive OfficerSep 16Sale67.699,000609,2106,664,868Sep 18 04:13 PM
Hoge StephenPresidentSep 14Option Exercise0.9910,0009,9001,956,530Sep 15 04:56 PM
Zaks Tal ZviChief Medical OfficerSep 14Option Exercise20.0320,034401,28320,034Sep 15 05:00 PM
Zaks Tal ZviChief Medical OfficerSep 14Sale62.6620,0341,255,3210Sep 15 05:00 PM
Hoge StephenPresidentSep 14Sale61.4220,0001,228,4681,936,530Sep 15 04:56 PM
Bancel StephaneChief Executive OfficerSep 11Sale58.4211,046645,259408,718Sep 15 04:48 PM
Bancel StephaneChief Executive OfficerSep 10Sale56.9617,030970,0297,764,880Sep 11 04:12 PM
Bancel StephaneChief Executive OfficerSep 09Sale55.819,000502,2906,674,868Sep 11 04:12 PM
Zaks Tal ZviChief Medical OfficerSep 08Option Exercise18.5126,467489,81226,467Sep 10 04:50 PM
Zaks Tal ZviChief Medical OfficerSep 08Sale56.2026,4671,487,3550Sep 10 04:50 PM
Bancel StephaneChief Executive OfficerSep 04Sale61.8711,046683,459419,764Sep 08 05:06 PM
Hoge StephenPresidentSep 03Option Exercise0.9910,0009,9001,956,530Sep 04 04:31 PM
Hoge StephenPresidentSep 03Sale65.6510,000656,5001,946,530Sep 04 04:31 PM
Bancel StephaneChief Executive OfficerSep 03Sale65.6510,000656,5007,774,880Sep 04 04:28 PM
Hoge StephenPresidentSep 02Option Exercise0.9910,0009,9001,956,530Sep 03 04:24 PM
Bancel StephaneChief Executive OfficerSep 02Sale62.899,000566,0106,684,868Sep 03 04:16 PM
Hoge StephenPresidentSep 02Sale62.8910,000628,9001,946,530Sep 03 04:24 PM
Bancel StephaneChief Executive OfficerSep 01Sale63.549,247587,5549,126,713Sep 03 04:16 PM
Zaks Tal ZviChief Medical OfficerAug 31Option Exercise17.7730,000532,95030,000Sep 01 04:18 PM
Zaks Tal ZviChief Medical OfficerAug 31Sale64.1030,0001,922,9500Sep 01 04:18 PM
Bancel StephaneChief Executive OfficerAug 28Sale66.6911,046736,640430,810Sep 01 04:12 PM
CDAK Codiak BioSciences, Inc. daily Stock Chart
CDAK [NASD]
Codiak BioSciences, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own2.80% Shs Outstand18.42M Perf Week13.92%
Market Cap165.78M Forward P/E- EPS next Y-3.61 Insider Trans0.00% Shs Float16.33M Perf Month-3.33%
Income-80.70M PEG- EPS next Q-5.50 Inst Own19.14% Short Float2.56% Perf Quarter-
Sales0.60M P/S276.30 EPS this Y-75.00% Inst Trans- Short Ratio1.67 Perf Half Y-
Book/sh- P/B- EPS next Y69.70% ROA- Target Price- Perf Year-
Cash/sh2.76 P/C3.26 EPS next 5Y- ROE- 52W Range7.90 - 14.40 Perf YTD-25.74%
Dividend- P/FCF- EPS past 5Y- ROI43.80% 52W High-37.50% Beta-
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low13.92% ATR0.72
Employees101 Current Ratio2.80 Sales Q/Q531.80% Oper. Margin- RSI (14)- Volatility6.10% 7.23%
OptionableNo Debt/Eq- EPS Q/Q13.80% Profit Margin- Rel Volume0.17 Prev Close8.57
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume251.30K Price9.00
Recom1.50 SMA202.83% SMA50-4.44% SMA200-4.44% Volume42,723 Change5.02%
Nov-09-20Initiated Wedbush Outperform $19
Nov-09-20Initiated Goldman Buy $29
Nov-23-20 07:30AM  
Nov-19-20 04:05PM  
Nov-09-20 08:00AM  
Oct-23-20 06:00PM  
Oct-13-20 07:04PM  
Codiak BioSciences, Inc. is harnessing exosomesAnatural intercellular messengersAto pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
VIR Vir Biotechnology, Inc. daily Stock Chart
VIR [NASD]
Vir Biotechnology, Inc.
Index- P/E- EPS (ttm)-6.40 Insider Own0.40% Shs Outstand125.81M Perf Week3.35%
Market Cap3.58B Forward P/E- EPS next Y-2.43 Insider Trans-50.42% Shs Float109.37M Perf Month-20.04%
Income-256.80M PEG- EPS next Q-0.71 Inst Own88.30% Short Float8.19% Perf Quarter-30.88%
Sales75.60M P/S47.38 EPS this Y-443.30% Inst Trans31.60% Short Ratio7.63 Perf Half Y-16.88%
Book/sh6.46 P/B4.40 EPS next Y-2.50% ROA-39.40% Target Price- Perf Year140.15%
Cash/sh6.56 P/C4.33 EPS next 5Y8.50% ROE-47.10% 52W Range11.65 - 75.00 Perf YTD125.92%
Dividend- P/FCF- EPS past 5Y- ROI-41.90% 52W High-62.12% Beta-
Dividend %- Quick Ratio11.00 Sales past 5Y- Gross Margin- 52W Low143.85% ATR2.13
Employees297 Current Ratio11.00 Sales Q/Q35.70% Oper. Margin- RSI (14)43.76 Volatility5.67% 7.11%
OptionableYes Debt/Eq0.00 EPS Q/Q-52.30% Profit Margin- Rel Volume0.46 Prev Close27.20
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume1.17M Price28.41
Recom2.40 SMA20-2.67% SMA50-15.83% SMA200-22.77% Volume539,675 Change4.45%
Oct-05-20Initiated BofA Securities Buy $55
Sep-14-20Upgrade Goldman Neutral → Buy $48 → $54
Sep-11-20Upgrade JP Morgan Underweight → Neutral $29
Aug-20-20Initiated Needham Buy $62
Mar-19-20Downgrade JP Morgan Neutral → Underweight $26
Mar-13-20Downgrade Goldman Buy → Neutral
Feb-27-20Downgrade Robert W. Baird Neutral → Underperform $17
Feb-04-20Downgrade JP Morgan Overweight → Neutral $25 → $26
Nov-14-19Initiated Robert W. Baird Neutral
Nov-05-19Initiated JP Morgan Overweight $25
Nov-05-19Initiated Goldman Buy $37
Nov-05-19Initiated Cowen Outperform
Nov-05-19Initiated Barclays Overweight $25
Nov-24-20 09:47AM  
Nov-16-20 02:55AM  
Nov-13-20 09:08AM  
Nov-10-20 04:01PM  
Nov-06-20 08:00AM  
Oct-27-20 04:01PM  
Oct-21-20 08:00AM  
Oct-13-20 04:01PM  
11:26AM  
Oct-12-20 09:31AM  
Oct-09-20 08:00AM  
Oct-07-20 01:44PM  
01:01PM  
08:47AM  
07:24AM  
Oct-06-20 04:25PM  
11:28AM  
10:46AM  
10:03AM  
09:49AM  
08:18AM  
Sep-29-20 06:08PM  
Sep-26-20 06:16AM  
Sep-24-20 08:00AM  
Sep-23-20 12:41PM  
Sep-22-20 10:01AM  
09:43AM  
Sep-15-20 06:30AM  
Sep-09-20 04:10PM  
Sep-08-20 04:01PM  
Sep-02-20 07:25AM  
Sep-01-20 04:01PM  
09:39AM  
09:09AM  
Aug-31-20 03:39PM  
03:17PM  
12:45PM  
08:50AM  
08:00AM  
Aug-20-20 09:51AM  
08:00AM  
Aug-11-20 04:01PM  
06:40AM  
Jul-28-20 04:01PM  
Jul-10-20 04:02PM  
04:01PM  
Jul-07-20 10:25PM  
05:58PM  
Jul-06-20 07:00AM  
Jun-08-20 02:06PM  
Jun-05-20 01:22PM  
Jun-04-20 03:57PM  
Jun-02-20 08:00AM  
Jun-01-20 12:23PM  
11:00AM  
May-29-20 08:00AM  
May-27-20 08:00AM  
May-23-20 08:13AM  
May-19-20 09:31AM  
May-18-20 05:28PM  
05:00PM  
02:47PM  
05:05AM  
May-15-20 03:09PM  
01:03PM  
May-12-20 04:01PM  
May-08-20 04:01PM  
May-07-20 04:01PM  
May-05-20 03:26PM  
03:11PM  
May-04-20 10:23AM  
08:24AM  
07:30AM  
Apr-28-20 08:00AM  
Apr-16-20 08:09AM  
Apr-15-20 04:01PM  
Apr-08-20 10:05AM  
07:00AM  
Apr-07-20 11:00AM  
Apr-06-20 04:03PM  
09:56AM  
08:12AM  
08:01AM  
Mar-30-20 07:00AM  
Mar-26-20 04:01PM  
10:52AM  
10:09AM  
08:23AM  
Mar-25-20 08:00AM  
Mar-18-20 05:49PM  
Mar-17-20 02:26PM  
Mar-16-20 03:41PM  
Mar-13-20 12:40PM  
11:01AM  
Mar-12-20 10:36AM  
10:07AM  
09:01AM  
08:00AM  
Mar-11-20 08:00AM  
Mar-10-20 08:25PM  
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Virgin HerbertEVP, Research & CSONov 24Option Exercise1.532,3403,58026,040Nov 25 05:00 PM
Virgin HerbertEVP, Research & CSONov 24Sale27.292,34063,84823,700Nov 25 05:00 PM
Pang PhillipChief Medical OfficerNov 12Option Exercise0.8620,00017,10049,777Nov 16 05:00 PM
Virgin HerbertEVP, Research & CSONov 10Option Exercise1.532,3403,58026,040Nov 12 05:00 PM
Virgin HerbertEVP, Research & CSONov 10Sale26.262,34061,44823,700Nov 12 05:00 PM
Pang PhillipChief Medical OfficerNov 04Option Exercise1.535,0007,65034,777Nov 05 05:00 PM
Parrish JayChief Business OfficerNov 02Option Exercise1.526,94410,520229,166Nov 03 05:00 PM
Parrish JayChief Business OfficerNov 02Sale31.276,944217,153222,222Nov 03 05:00 PM
Virgin HerbertEVP, Research & CSOOct 27Option Exercise1.533,8055,82227,505Oct 28 07:43 PM
Virgin HerbertEVP, Research & CSOOct 27Sale35.043,805133,33523,700Oct 28 07:43 PM
Pang PhillipChief Medical OfficerOct 21Option Exercise2.2112,50027,66742,277Oct 22 06:15 PM
Pang PhillipChief Medical OfficerOct 21Sale35.4912,500443,60829,777Oct 22 06:15 PM
Pang PhillipChief Medical OfficerOct 21Sale31.445,000157,20929,777Nov 05 05:00 PM
Virgin HerbertEVP, Research & CSOOct 13Option Exercise1.535,5608,50729,260Oct 14 06:33 PM
Virgin HerbertEVP, Research & CSOOct 13Sale43.035,560239,23623,700Oct 14 06:33 PM
Pang PhillipChief Medical OfficerOct 07Option Exercise1.5412,50019,22942,277Oct 08 05:00 PM
Pang PhillipChief Medical OfficerOct 07Sale41.7412,500521,79529,777Oct 08 05:00 PM
Parrish JayChief Business OfficerOct 01Option Exercise1.526,94510,522229,167Oct 02 05:19 PM
Parrish JayChief Business OfficerOct 01Sale34.756,945241,342222,222Oct 02 05:19 PM
Virgin HerbertEVP, Research & CSOSep 29Option Exercise1.533,5105,37027,210Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 29Sale38.003,510133,38023,700Oct 01 05:00 PM
Virgin HerbertEVP, Research & CSOSep 24Option Exercise1.533,7005,66123,700Sep 28 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Option Exercise1.533,8055,82223,805Sep 23 05:00 PM
Virgin HerbertEVP, Research & CSOSep 22Sale31.713,805120,63820,000Sep 23 05:00 PM
Pang PhillipChief Medical OfficerSep 16Option Exercise2.2412,50028,00142,277Sep 18 05:00 PM
Pang PhillipChief Medical OfficerSep 16Sale31.9012,500398,69429,777Sep 18 05:00 PM
Virgin HerbertEVP, Research & CSOSep 08Option Exercise1.533,8055,82223,805Sep 10 04:30 PM
Virgin HerbertEVP, Research & CSOSep 08Sale29.993,805114,09820,000Sep 10 04:30 PM
Pang PhillipChief Medical OfficerSep 02Option Exercise1.5812,50019,68842,277Sep 03 04:23 PM
Pang PhillipChief Medical OfficerSep 02Sale32.8912,500411,15929,777Sep 03 04:23 PM
Parrish JayChief Business OfficerSep 01Option Exercise1.586,94310,935229,165Sep 03 04:22 PM
Parrish JayChief Business OfficerSep 01Sale39.156,943271,796222,222Sep 03 04:22 PM
Virgin HerbertEVP, Research & CSOAug 25Option Exercise1.5325,56039,10725,560Sep 10 04:29 PM
Virgin HerbertEVP, Research & CSOAug 25Sale42.925,560238,63220,000Sep 10 04:29 PM
Pang PhillipChief Medical OfficerAug 19Option Exercise1.5126,50039,99242,277Aug 21 04:39 PM
Pang PhillipChief Medical OfficerAug 19Sale50.9512,500636,85529,777Aug 21 04:39 PM
Virgin HerbertEVP, Research & CSOAug 11Option Exercise1.537,90012,0877,900Aug 12 04:30 PM
Virgin HerbertEVP, Research & CSOAug 11Sale51.087,900403,5630Aug 12 04:30 PM
Pang PhillipChief Medical OfficerAug 05Option Exercise1.5812,50019,68828,277Aug 07 05:40 PM
Pang PhillipChief Medical OfficerAug 05Option Exercise1.5812,50019,68828,277Aug 07 05:07 PM
Pang PhillipChief Medical OfficerAug 05Sale50.9012,500636,22215,777Aug 07 05:07 PM
Pang PhillipChief Medical OfficerAug 05Sale50.9012,500636,22215,777Aug 07 05:40 PM
Parrish JayChief Business OfficerAug 03Option Exercise1.5011,11016,665233,332Aug 04 05:14 PM
Parrish JayChief Business OfficerAug 03Sale47.6511,110529,404222,222Aug 04 05:14 PM
Virgin HerbertEVP, Research & CSOJul 28Option Exercise1.537,90012,0877,900Jul 30 07:28 PM
Virgin HerbertEVP, Research & CSOJul 28Option Exercise1.537,90012,0877,900Jul 30 07:03 PM
Virgin HerbertEVP, Research & CSOJul 28Sale47.997,900379,0900Jul 30 07:03 PM
Virgin HerbertEVP, Research & CSOJul 28Sale47.997,900379,0900Jul 30 07:28 PM
Pang PhillipChief Medical OfficerJul 15Option Exercise2.2412,50028,01828,277Jul 16 05:00 PM
Pang PhillipChief Medical OfficerJul 15Sale49.5312,500619,11815,777Jul 16 05:00 PM
Virgin HerbertEVP, Research & CSOJul 14Option Exercise1.537,90012,0877,900Jul 16 05:00 PM
Virgin HerbertEVP, Research & CSOJul 14Sale48.857,900385,8760Jul 16 05:00 PM
Horn HowardCFOJul 13Sale50.0630,0001,501,731177,777Jul 15 04:50 PM
Horn HowardCFOJul 02Sale40.0010,000400,000207,777Jul 02 06:42 PM
Pang PhillipChief Medical OfficerJul 01Option Exercise4.3712,50054,68728,277Jul 02 06:42 PM
Parrish JayChief Business OfficerJul 01Option Exercise1.5475,000115,792297,222Jul 02 06:43 PM
Horn HowardCFOJul 01Sale37.8410,000378,399217,777Jul 02 06:42 PM
Pang PhillipChief Medical OfficerJul 01Sale37.7812,500472,25215,777Jul 02 06:42 PM
Parrish JayChief Business OfficerJul 01Sale37.9575,0002,846,310222,222Jul 02 06:43 PM
Horn HowardCFOJun 25Sale50.0030,0001,500,000227,777Jun 26 05:00 PM
Virgin HerbertEVP, Research & CSOJun 24Option Exercise1.539,36014,3219,360Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 24Sale48.009,360449,2800Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 23Option Exercise1.535,5608,5075,560Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 23Sale38.995,560216,7780Jun 24 08:23 PM
Virgin HerbertEVP, Research & CSOJun 19Option Exercise1.533,5105,3703,510Jun 23 05:00 PM
Virgin HerbertEVP, Research & CSOJun 19Sale38.003,510133,3840Jun 23 05:00 PM
Horn HowardCFOJun 19Sale40.0010,000400,000257,777Jun 23 05:00 PM
Pang PhillipChief Medical OfficerJun 17Option Exercise5.1812,50064,68828,277Jun 18 05:00 PM
Pang PhillipChief Medical OfficerJun 17Sale37.2712,500465,81515,777Jun 18 05:00 PM
Virgin HerbertEVP, Research & CSOJun 09Option Exercise1.533,8055,8223,805Jun 11 05:00 PM
Virgin HerbertEVP, Research & CSOJun 09Sale36.283,805138,0300Jun 11 05:00 PM
Pang PhillipChief Medical OfficerJun 03Option Exercise5.1812,50064,68828,277Jun 04 04:53 PM
Pang PhillipChief Medical OfficerJun 03Sale35.0712,500438,38715,777Jun 04 04:53 PM
Parrish JayChief Business OfficerJun 01Option Exercise1.4975,000111,375297,222Jun 02 09:15 PM
Parrish JayChief Business OfficerJun 01Sale35.2275,0002,641,410222,222Jun 02 09:15 PM
Horn HowardCFOJun 01Sale35.1010,000351,038267,777Jun 02 09:14 PM
Virgin HerbertEVP, Research & CSOMay 26Option Exercise1.533,8055,8223,805May 27 05:00 PM
Virgin HerbertEVP, Research & CSOMay 26Sale34.083,805129,6740May 27 05:00 PM
Virgin HerbertEVP, Research & CSOMay 18Option Exercise1.531,7552,6851,755May 19 05:21 PM
Virgin HerbertEVP, Research & CSOMay 18Sale38.001,75566,6900May 19 05:21 PM
Parrish JayChief Business OfficerMay 14Option Exercise1.4975,000111,375297,222May 15 07:18 PM
Virgin HerbertEVP, Research & CSOMay 14Option Exercise1.533,8055,8223,805May 15 07:48 PM
Virgin HerbertEVP, Research & CSOMay 14Sale30.073,805114,4180May 15 07:48 PM
Parrish JayChief Business OfficerMay 14Sale30.0575,0002,253,885222,222May 15 07:18 PM
MORE ROBERT JDirectorMay 01Sale28.0018,458516,85371,534May 05 05:55 PM
Pang PhillipChief Medical OfficerApr 17Option Exercise0.868,0006,84015,777Apr 20 08:20 PM
KOD Kodiak Sciences Inc. daily Stock Chart
KOD [NASD]
Kodiak Sciences Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own0.10% Shs Outstand45.12M Perf Week4.09%
Market Cap5.84B Forward P/E- EPS next Y-4.45 Insider Trans- Shs Float36.56M Perf Month35.26%
Income-102.10M PEG- EPS next Q-0.86 Inst Own83.10% Short Float9.22% Perf Quarter160.29%
Sales- P/S- EPS this Y-11.40% Inst Trans-3.59% Short Ratio8.50 Perf Half Y104.61%
Book/sh6.25 P/B21.15 EPS next Y-63.00% ROA-23.90% Target Price108.94 Perf Year379.85%
Cash/sh8.62 P/C15.34 EPS next 5Y12.40% ROE-32.30% 52W Range24.41 - 141.98 Perf YTD83.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-6.89% Beta-
Dividend %- Quick Ratio17.00 Sales past 5Y- Gross Margin- 52W Low441.58% ATR10.91
Employees62 Current Ratio17.00 Sales Q/Q- Oper. Margin- RSI (14)67.00 Volatility9.67% 9.81%
OptionableYes Debt/Eq0.00 EPS Q/Q-141.40% Profit Margin- Rel Volume1.21 Prev Close121.99
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume396.78K Price132.20
Recom2.20 SMA2016.93% SMA5053.17% SMA200114.12% Volume473,807 Change8.37%
Nov-16-20Downgrade Morgan Stanley Overweight → Equal-Weight $80 → $125
Nov-13-20Downgrade Goldman Buy → Neutral $83 → $105
Mar-31-20Initiated BMO Capital Markets Outperform $74
Mar-03-20Initiated Goldman Buy $80
Feb-18-20Downgrade Barclays Overweight → Equal Weight $69
Feb-06-20Initiated SunTrust Buy
Jan-08-20Initiated ROTH Capital Buy $115
Jan-03-20Initiated Jefferies Buy $100
Dec-24-19Initiated JP Morgan Overweight $82
Oct-15-19Reiterated Chardan Capital Markets Buy $22.50 → $35
Feb-20-19Initiated Chardan Capital Markets Buy $22.50
Oct-29-18Initiated Morgan Stanley Overweight $20
Oct-29-18Initiated BofA/Merrill Buy $14
Oct-29-18Initiated Barclays Overweight $20
Nov-20-20 04:03PM  
Nov-17-20 09:02PM  
01:16PM  
Nov-16-20 04:01PM  
06:53AM  
Nov-12-20 04:12PM  
Nov-11-20 11:27PM  
Nov-10-20 11:44AM  
Nov-09-20 05:30AM  
Oct-26-20 07:53AM  
Oct-12-20 04:56PM  
Oct-05-20 09:02AM  
Sep-02-20 04:08PM  
Aug-10-20 05:30AM  
Jul-31-20 06:00AM  
Jul-16-20 04:38PM  
Jul-10-20 04:00PM  
Jul-07-20 08:38AM  
Jul-05-20 03:30PM  
Jun-12-20 10:20PM  
Jun-05-20 12:00PM  
May-29-20 01:38PM  
May-28-20 08:22AM  
May-26-20 11:02AM  
May-13-20 07:01AM  
May-11-20 04:13PM  
05:30AM  
May-08-20 04:30PM  
Apr-07-20 11:35AM  
Apr-02-20 04:08PM  
Mar-24-20 04:23PM  
08:51AM  
Mar-23-20 01:37PM  
Mar-18-20 02:29PM  
Mar-16-20 05:30AM  
Mar-03-20 12:08PM  
Feb-27-20 06:00AM  
Feb-21-20 03:14PM  
Feb-08-20 03:30PM  
Jan-14-20 03:56PM  
Jan-08-20 06:00AM  
Dec-27-19 02:19PM  
Dec-26-19 07:55AM  
Dec-25-19 11:30AM  
Dec-24-19 12:00PM  
Dec-22-19 01:21PM  
Dec-20-19 07:30AM  
Dec-19-19 04:01PM  
12:20PM  
Dec-14-19 07:30AM  
Dec-06-19 04:15PM  
Dec-03-19 09:07PM  
08:41AM  
07:59AM  
Dec-02-19 05:00PM  
09:51AM  
07:00AM  
06:00AM  
Nov-27-19 12:15PM  
Nov-12-19 07:20AM  
05:30AM  
Nov-08-19 07:00AM  
Oct-11-19 07:58PM  
06:00AM  
Oct-10-19 07:39PM  
Oct-07-19 06:00AM  
Oct-04-19 02:27PM  
Sep-15-19 06:08AM  
Sep-12-19 06:00AM  
Sep-06-19 06:00AM  
Sep-04-19 06:30PM  
Aug-23-19 11:36AM  
Aug-14-19 05:30AM  
Aug-08-19 06:00AM  
Jul-27-19 12:47PM  
Jul-24-19 07:00AM  
Jul-17-19 10:09AM  
Jun-17-19 09:56AM  
May-30-19 07:27PM  
May-25-19 10:26AM  
May-24-19 09:46AM  
May-15-19 06:00AM  
May-09-19 07:00AM  
Apr-25-19 04:05PM  
Mar-28-19 06:00AM  
Mar-07-19 06:00AM  
Mar-01-19 10:28AM  
Feb-28-19 08:15AM  
Feb-27-19 11:00AM  
Feb-08-19 07:00AM  
Jan-18-19 10:35AM  
Dec-24-18 08:00AM  
Dec-21-18 06:00AM  
Dec-05-18 10:35AM  
Nov-16-18 06:00AM  
Oct-31-18 03:34PM  
Oct-26-18 03:05PM  
Oct-10-18 07:00AM  
Oct-04-18 11:35AM  
06:42AM  
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EHRLICH JASONSee RemarksNov 20Option Exercise10.296,95071,51649,793Nov 24 06:04 PM
EHRLICH JASONSee RemarksNov 20Sale138.796,950964,60142,843Nov 24 06:04 PM
EHRLICH JASONSee RemarksOct 27Option Exercise10.297,50077,17550,343Oct 29 04:49 PM
EHRLICH JASONSee RemarksOct 27Sale100.007,500750,00042,843Oct 29 04:49 PM
EHRLICH JASONSee RemarksOct 23Option Exercise10.297,50077,17550,343Oct 27 04:57 PM
EHRLICH JASONSee RemarksOct 23Sale86.257,500646,87542,843Oct 27 04:57 PM
EHRLICH JASONSee RemarksOct 20Option Exercise10.296,95071,51649,793Oct 22 04:56 PM
EHRLICH JASONSee RemarksOct 20Sale78.396,950544,81742,843Oct 22 04:56 PM
EHRLICH JASONSee RemarksOct 13Option Exercise10.295,00051,45047,843Oct 15 05:44 PM
EHRLICH JASONSee RemarksOct 13Sale75.005,000375,00042,843Oct 15 05:44 PM
EHRLICH JASONSee RemarksOct 09Sale71.282,200156,81942,843Oct 13 07:04 PM
BAKER BROS. ADVISORS LPDirectorSep 25Buy56.6548,1252,726,18211,324,937Sep 25 06:02 PM
BAKER BROS. ADVISORS LPDirectorSep 24Buy52.0236,0201,873,92411,280,001Sep 24 07:30 PM
BAKER BROS. ADVISORS LPDirectorSep 23Buy52.4392,0694,826,75611,246,368Sep 24 07:30 PM
BAKER BROS. ADVISORS LPDirectorSep 22Buy50.6774,9583,797,91111,160,400Sep 24 07:30 PM
EHRLICH JASONSee RemarksSep 21Option Exercise10.296,95071,51640,934Sep 23 06:15 PM
EHRLICH JASONSee RemarksSep 21Sale52.406,950364,18233,984Sep 23 06:15 PM
BAKER BROS. ADVISORS LPDirectorSep 08Buy47.34116,2955,505,93411,090,409Sep 08 05:58 PM
BAKER BROS. ADVISORS LPDirectorSep 04Buy46.7382,8013,869,47310,982,772Sep 08 05:58 PM
BAKER BROS. ADVISORS LPDirectorSep 03Buy47.97123,8835,942,90410,905,982Sep 08 05:58 PM
BAKER BROS. ADVISORS LPDirectorAug 21Buy48.63139,0446,762,05610,791,092Aug 21 05:19 PM
EHRLICH JASONSee RemarksAug 20Option Exercise10.296,95071,51640,934Aug 24 04:56 PM
BAKER BROS. ADVISORS LPDirectorAug 20Buy47.4060,5732,871,15610,662,260Aug 21 05:19 PM
EHRLICH JASONSee RemarksAug 20Sale47.116,950327,44433,984Aug 24 04:56 PM
BAKER BROS. ADVISORS LPDirectorAug 19Buy46.993,869181,79110,606,135Aug 21 05:19 PM
EHRLICH JASONSee RemarksJul 20Option Exercise10.296,95071,51640,934Jul 22 04:47 PM
EHRLICH JASONSee RemarksJul 20Sale50.446,950350,52633,984Jul 22 04:47 PM
EHRLICH JASONSee RemarksJul 02Option Exercise10.292,70027,78333,984Jul 07 07:05 PM
EHRLICH JASONSee RemarksJun 22Option Exercise10.296,95071,51638,234Jun 24 05:09 PM
EHRLICH JASONSee RemarksJun 22Sale60.546,950420,74731,284Jun 24 05:09 PM
EHRLICH JASONSee RemarksMay 20Option Exercise10.296,95071,51638,234May 22 04:41 PM
EHRLICH JASONSee RemarksMay 20Sale60.726,950421,98931,284May 22 04:41 PM
EHRLICH JASONSee RemarksApr 20Option Exercise10.296,95071,51638,234Apr 22 05:01 PM
EHRLICH JASONSee RemarksApr 20Sale54.126,950376,11531,284Apr 22 05:01 PM
EHRLICH JASONSee RemarksApr 09Sale48.562,200106,83031,284Apr 13 06:37 PM
Liang HongSVP, Discovery MedicineApr 02Sale42.344,000169,360130,166Apr 06 08:08 PM
Liang HongSVP, Discovery MedicineMar 26Sale47.784,000191,112134,166Mar 30 04:51 PM
EHRLICH JASONSee RemarksMar 20Option Exercise10.296,95071,51629,492Mar 24 04:45 PM
Levy Richard SDirectorMar 20Buy44.331,00044,3301,000Mar 24 04:50 PM
EHRLICH JASONSee RemarksMar 20Sale45.006,950312,76222,542Mar 24 04:45 PM
Liang HongSVP, Discovery MedicineMar 19Sale39.454,000157,811138,166Mar 23 04:36 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy37.3735,4001,322,97710,602,550Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy38.9910,000389,85010,570,083Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy39.97104,6004,180,97710,560,911Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Buy57.99100,0005,799,44110,464,977Feb 26 05:06 PM
BAKER BROS. ADVISORS LPDirectorFeb 25Buy57.91206,12611,937,24810,373,248Feb 26 05:06 PM
BAKER BROS. ADVISORS LPDirectorFeb 24Buy57.5671,1234,093,55310,184,170Feb 26 05:06 PM
EHRLICH JASONSee RemarksDec 23Option Exercise10.291,07511,06222,542Dec 27 05:53 PM
BAKER BROS. ADVISORS LPDirectorDec 06Buy46.001,902,17387,499,95810,118,929Dec 06 04:46 PM
Liang HongSVP, Discovery MedicineDec 02Option Exercise1.0542,16644,111142,166Dec 04 05:33 PM
ALGS Aligos Therapeutics, Inc. daily Stock Chart
ALGS [NASD]
Aligos Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.98 Insider Own22.70% Shs Outstand37.70M Perf Week-10.29%
Market Cap676.72M Forward P/E- EPS next Y-2.97 Insider Trans0.00% Shs Float28.53M Perf Month15.81%
Income-73.10M PEG- EPS next Q-0.78 Inst Own28.07% Short Float6.85% Perf Quarter-
Sales- P/S- EPS this Y-275.10% Inst Trans- Short Ratio6.85 Perf Half Y-
Book/sh- P/B- EPS next Y22.30% ROA- Target Price30.50 Perf Year-
Cash/sh2.34 P/C7.68 EPS next 5Y- ROE- 52W Range12.82 - 22.50 Perf YTD20.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.22% Beta-
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low40.02% ATR1.75
Employees67 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)- Volatility9.71% 11.41%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.11 Prev Close18.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume285.41K Price17.95
Recom1.70 SMA203.92% SMA508.39% SMA2008.39% Volume33,017 Change-0.28%
Nov-10-20Initiated Piper Sandler Overweight $35
Nov-10-20Initiated JP Morgan Overweight $33
Nov-10-20Initiated Jefferies Buy $26
Nov-10-20Initiated Cantor Fitzgerald Overweight $28
Nov-18-20 10:48AM  
Nov-16-20 08:00AM  
Nov-13-20 08:00AM  
Nov-12-20 08:00AM  
Oct-30-20 08:00AM  
Oct-23-20 06:00PM  
Oct-16-20 06:05PM  
05:22PM  
02:13PM  
Oct-15-20 10:19PM  
Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR- agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California.
MBOT Microbot Medical Inc. daily Stock Chart
MBOT [NASD]
Microbot Medical Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own4.25% Shs Outstand7.11M Perf Week-3.20%
Market Cap51.69M Forward P/E- EPS next Y-1.34 Insider Trans-16.57% Shs Float6.81M Perf Month-1.49%
Income-8.40M PEG- EPS next Q-0.34 Inst Own14.60% Short Float6.52% Perf Quarter5.06%
Sales- P/S- EPS this Y32.10% Inst Trans10.07% Short Ratio2.51 Perf Half Y-3.71%
Book/sh3.73 P/B1.95 EPS next Y-7.20% ROA-26.60% Target Price- Perf Year54.03%
Cash/sh- P/C- EPS next 5Y- ROE-29.00% 52W Range4.30 - 20.15 Perf YTD-28.52%
Dividend- P/FCF- EPS past 5Y71.10% ROI- 52W High-63.92% Beta4.08
Dividend %- Quick Ratio29.30 Sales past 5Y- Gross Margin- 52W Low69.07% ATR0.34
Employees8 Current Ratio29.30 Sales Q/Q- Oper. Margin- RSI (14)43.37 Volatility4.21% 4.51%
OptionableNo Debt/Eq0.00 EPS Q/Q20.00% Profit Margin- Rel Volume1.01 Prev Close7.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume176.73K Price7.27
Recom2.00 SMA20-1.01% SMA50-4.10% SMA2002.14% Volume180,022 Change0.28%
Jan-13-20Reiterated H.C. Wainwright Buy $12 → $26
Dec-24-19Reiterated H.C. Wainwright Buy $10 → $12
Jan-31-18Initiated Ladenburg Thalmann Buy $1.75
Nov-17-20 07:00AM  
Nov-09-20 07:00AM  
Oct-07-20 07:00AM  
Aug-20-20 10:00AM  
Aug-17-20 07:30AM  
Aug-13-20 09:00AM  
Aug-03-20 07:00AM  
Jul-01-20 07:17AM  
Apr-01-20 07:00AM  
Mar-03-20 07:00AM  
Jan-15-20 08:39AM  
Jan-10-20 09:33AM  
Jan-09-20 06:19AM  
Jan-08-20 07:00AM  
Dec-31-19 10:57AM  
Dec-30-19 02:15PM  
12:08PM  
Dec-27-19 02:15PM  
01:47PM  
12:30PM  
10:00AM  
Dec-26-19 07:55AM  
06:00AM  
Dec-23-19 07:00AM  
Nov-25-19 07:00AM  
Nov-01-19 11:01AM  
Oct-30-19 07:00AM  
Sep-13-19 07:30AM  
Sep-10-19 07:30AM  
Sep-05-19 04:05PM  
Jul-24-19 09:04AM  
07:30AM  
Apr-23-19 07:00AM  
Mar-04-19 08:07AM  
Mar-01-19 05:23PM  
Jan-24-19 09:30AM  
Jan-23-19 03:26PM  
02:35PM  
Jan-22-19 01:27PM  
Jan-17-19 08:32AM  
Jan-16-19 09:26AM  
Jan-15-19 09:07PM  
02:34PM  
02:29PM  
02:08PM  
08:00AM  
Jan-14-19 05:49PM  
09:15AM  
08:38AM  
07:01AM  
07:00AM  
Jan-07-19 07:00AM  
Nov-19-18 08:10AM  
Oct-01-18 10:00AM  
07:00AM  
Jun-25-18 09:00AM  
Jun-18-18 07:00AM  
May-30-18 07:00AM  
May-29-18 07:00AM  
May-25-18 07:00AM  
May-23-18 09:02AM  
07:00AM  
07:00AM  
May-21-18 07:00AM  
May-15-18 08:11PM  
May-09-18 07:00AM  
May-02-18 07:00AM  
Apr-16-18 04:01PM  
Apr-12-18 07:00AM  
Apr-05-18 04:01PM  
Feb-13-18 08:30AM  
Jan-31-18 07:00AM  
Jan-08-18 07:00AM  
Dec-14-17 07:00AM  
Dec-12-17 07:00AM  
Dec-06-17 05:01PM  
Nov-08-17 08:00AM  
Sep-25-17 11:00AM  
Sep-18-17 08:20AM  
Sep-15-17 07:00AM  
Sep-07-17 04:30PM  
Aug-23-17 07:20AM  
Aug-14-17 04:01PM  
03:00PM  
Aug-10-17 04:01PM  
Jun-14-17 07:00AM  
Jun-09-17 07:30AM  
Jun-05-17 09:25AM  
09:05AM  
May-31-17 07:30AM  
May-15-17 07:30AM  
Mar-30-17 04:24PM  
Mar-29-17 04:01PM  
Mar-25-17 01:04PM  
Mar-21-17 02:16PM  
Mar-15-17 02:43PM  
Mar-13-17 07:00AM  
Feb-24-17 11:14AM  
Feb-23-17 07:00AM  
Feb-22-17 10:00AM  
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 37 issued/allowed patents and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bornstein YosephDirectorOct 19Sale7.944,88138,735242,028Oct 21 05:22 PM
Bornstein YosephDirectorOct 05Sale7.8420,000156,898246,909Oct 13 05:00 PM
Bornstein YosephDirectorOct 05Sale7.7420,000154,850266,909Oct 06 04:58 PM
Bornstein YosephDirectorAug 17Sale10.1915,119154,093286,909Aug 19 04:30 PM
Gadot HarelChairman, President and CEODec 23Sale10.0040,000400,000136,847Dec 26 07:36 AM
CHRS Coherus BioSciences, Inc. daily Stock Chart
CHRS [NASD]
Coherus BioSciences, Inc.
Index- P/E8.95 EPS (ttm)2.02 Insider Own0.50% Shs Outstand71.65M Perf Week1.35%
Market Cap1.28B Forward P/E17.08 EPS next Y1.06 Insider Trans-47.14% Shs Float64.17M Perf Month1.23%
Income161.80M PEG4.07 EPS next Q0.26 Inst Own- Short Float25.33% Perf Quarter-4.85%
Sales489.30M P/S2.62 EPS this Y138.10% Inst Trans-0.31% Short Ratio18.12 Perf Half Y-3.17%
Book/sh3.57 P/B5.06 EPS next Y-41.31% ROA26.60% Target Price29.90 Perf Year1.75%
Cash/sh7.09 P/C2.55 EPS next 5Y2.20% ROE88.40% 52W Range10.86 - 23.03 Perf YTD0.25%
Dividend- P/FCF9.71 EPS past 5Y16.20% ROI37.00% 52W High-21.62% Beta1.64
Dividend %- Quick Ratio5.20 Sales past 5Y62.80% Gross Margin93.10% 52W Low66.18% ATR0.75
Employees306 Current Ratio5.40 Sales Q/Q1.70% Oper. Margin37.80% RSI (14)50.70 Volatility3.36% 4.27%
OptionableYes Debt/Eq1.58 EPS Q/Q-44.50% Profit Margin33.10% Rel Volume1.22 Prev Close18.70
ShortableYes LT Debt/Eq1.58 EarningsNov 05 AMC Payout0.00% Avg Volume897.14K Price18.05
Recom1.90 SMA201.79% SMA500.45% SMA2001.28% Volume1,082,111 Change-3.48%
Jul-16-20Initiated BofA Securities Neutral $20
Apr-17-20Initiated SunTrust Buy $26
Aug-13-19Initiated Mizuho Buy
Aug-02-19Reiterated Maxim Group Buy $25 → $27
Aug-02-19Reiterated H.C. Wainwright Buy $28 → $29
Jun-11-19Initiated Barclays Overweight $30
May-07-19Initiated H.C. Wainwright Buy $28
Aug-28-18Initiated H.C. Wainwright Buy $28
Mar-09-18Reiterated Maxim Group Buy $20 → $15
Aug-08-17Reiterated JP Morgan Overweight $32 → $25
Jun-13-17Reiterated Maxim Group Buy $44 → $40
May-05-17Initiated BMO Capital Markets Outperform $54
Oct-19-16Initiated Robert W. Baird Outperform $40
Sep-07-16Initiated Maxim Group Buy $43
Jul-27-16Initiated Citigroup Buy $36
Jan-20-16Initiated Credit Suisse Outperform
Nov-20-20 04:01PM  
Nov-09-20 09:30AM  
Nov-07-20 08:22AM  
Nov-06-20 03:30PM  
Nov-05-20 05:35PM  
04:02PM  
02:45PM  
Oct-29-20 12:40PM  
12:34PM  
Oct-26-20 12:10PM  
12:00PM  
11:40AM  
09:51AM  
Oct-22-20 04:15PM  
Oct-16-20 09:30AM  
Oct-05-20 09:44AM  
Sep-28-20 05:23PM  
Sep-18-20 11:02AM  
Sep-13-20 10:10AM  
Aug-21-20 09:30AM  
Aug-11-20 03:45PM  
Aug-06-20 08:10PM  
04:02PM  
Aug-03-20 04:48PM  
Jul-30-20 12:33PM  
Jul-17-20 09:30AM  
Jul-16-20 09:30AM  
Jul-14-20 03:49PM  
Jul-09-20 08:56PM  
Jun-19-20 09:30AM  
Jun-15-20 04:05PM  
Jun-12-20 08:31AM  
Jun-03-20 03:35AM  
May-26-20 06:16PM  
12:53PM  
May-21-20 12:47PM  
May-13-20 07:08PM  
May-10-20 10:47PM  
08:59AM  
May-08-20 05:30PM  
01:05PM  
May-07-20 04:08PM  
May-04-20 09:30AM  
Apr-30-20 12:34PM  
Apr-22-20 09:30AM  
Apr-21-20 05:39PM  
Apr-16-20 07:27AM  
Apr-15-20 12:05AM  
Apr-14-20 07:52AM  
Apr-13-20 09:23AM  
Apr-08-20 10:49AM  
Apr-07-20 06:59AM  
Mar-26-20 08:34AM  
Mar-20-20 09:30AM  
Mar-14-20 02:43AM  
Mar-09-20 05:01AM  
Mar-05-20 04:09PM  
07:00AM  
Feb-29-20 08:54AM  
Feb-27-20 04:01PM  
Feb-26-20 09:30AM  
Feb-24-20 09:43AM  
Feb-20-20 11:19AM  
Feb-11-20 11:30AM  
Feb-07-20 12:00PM  
Feb-06-20 09:34AM  
Jan-23-20 11:30AM  
Jan-17-20 08:16AM  
Jan-13-20 08:30AM  
Jan-08-20 08:53AM  
Jan-07-20 11:30AM  
09:59AM  
Jan-03-20 09:55AM  
09:30AM  
09:01AM  
Dec-30-19 09:44AM  
Dec-19-19 11:30AM  
Dec-16-19 09:34AM  
Dec-07-19 12:25PM  
Dec-03-19 08:51AM  
Nov-26-19 11:27AM  
Nov-19-19 09:36AM  
Nov-15-19 11:17PM  
10:08AM  
Nov-12-19 09:30AM  
08:18AM  
Nov-11-19 09:28AM  
Nov-08-19 09:30AM  
Nov-06-19 06:15PM  
04:01PM  
04:01PM  
Oct-29-19 03:16PM  
Oct-28-19 11:18AM  
Oct-26-19 01:22PM  
Oct-21-19 07:44AM  
Oct-18-19 09:30AM  
Oct-15-19 09:30AM  
Sep-25-19 04:37PM  
Sep-20-19 09:30AM  
Sep-10-19 03:18PM  
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anicetti Vincent RChief Operating OfficerNov 18Option Exercise12.704,28354,39436,852Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerNov 18Sale18.004,28377,09432,569Nov 19 04:16 PM
Viret Jean-FredericChief Financial OfficerNov 17Option Exercise13.501,50020,25040,269Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerNov 17Option Exercise2.502,5006,25151,056Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerNov 17Sale17.6618,487326,41632,569Nov 19 04:16 PM
Viret Jean-FredericChief Financial OfficerNov 17Sale17.491,99534,89638,769Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerOct 19Option Exercise4.773,21715,35751,773Oct 21 04:04 PM
Anicetti Vincent RChief Operating OfficerOct 19Sale17.893,21757,55648,556Oct 21 04:04 PM
Viret Jean-FredericChief Financial OfficerOct 14Sale19.006,144116,73640,423Oct 16 04:19 PM
Anicetti Vincent RChief Operating OfficerSep 17Option Exercise7.605,00038,00153,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerSep 17Sale18.845,00094,21648,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerAug 17Option Exercise7.605,00038,00153,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerAug 17Sale19.375,00096,85148,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerJul 17Option Exercise11.0015,000165,00163,556Jul 21 05:04 PM
Anicetti Vincent RChief Operating OfficerJul 17Sale18.2515,000273,68748,556Jul 21 05:04 PM
Lanfear Dennis MPresident & CEOJul 01Option Exercise0.0129,994249193,258Jul 06 05:58 PM
Szela Mary TDirectorJun 22Option Exercise8.8454,997485,90054,997Jun 24 04:55 PM
Szela Mary TDirectorJun 22Sale17.5854,997966,7590Jun 24 04:55 PM
Anicetti Vincent RChief Operating OfficerJun 17Option Exercise2.502,5006,25151,056Jun 19 04:35 PM
Anicetti Vincent RChief Operating OfficerJun 17Sale17.222,50043,05048,556Jun 19 04:35 PM
Wahlstrom MatsDirectorJun 17Sale17.15200,0003,430,0200Jun 19 04:33 PM
Viret Jean-FredericChief Financial OfficerMay 20Sale17.661,27822,56946,567May 22 04:30 PM
Anicetti Vincent RChief Operating OfficerMay 18Option Exercise2.502,5006,25151,056May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerMay 18Sale17.173,09353,10748,556May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerApr 20Sale17.005,15087,55047,846Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Option Exercise2.505,00012,50357,996Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Sale15.575,00077,85052,996Apr 21 04:24 PM
Wahlstrom MatsDirectorMar 03Sale20.12118,0662,375,409200,000Mar 05 04:31 PM
Viret Jean-FredericChief Financial OfficerFeb 19Option Exercise10.053,15931,74850,000Feb 21 06:16 PM
Viret Jean-FredericChief Financial OfficerFeb 19Sale22.333,15970,55246,841Feb 21 06:16 PM
Anicetti Vincent RChief Operating OfficerFeb 18Option Exercise7.605,00038,00160,496Feb 20 04:07 PM
Anicetti Vincent RChief Operating OfficerFeb 18Sale21.6410,000216,39052,996Feb 20 04:07 PM
Anicetti Vincent RChief Operating OfficerJan 17Option Exercise7.605,00038,00165,496Jan 22 04:06 PM
Anicetti Vincent RChief Operating OfficerJan 17Sale19.5910,000195,93157,996Jan 22 04:06 PM
Viret Jean-FredericChief Financial OfficerJan 15Option Exercise10.056,31863,49653,159Jan 17 04:11 PM
Viret Jean-FredericChief Financial OfficerJan 15Sale19.856,318125,42446,841Jan 17 04:11 PM
HEALY JAMESDirectorJan 12Option Exercise12.3720,000247,40070,086Jan 13 04:45 PM
HEALY JAMESDirectorJan 09Option Exercise5.0249,994251,00050,086Jan 13 04:45 PM
Anicetti Vincent RChief Operating OfficerDec 16Option Exercise2.502,5006,25121,826Dec 18 04:28 PM
Anicetti Vincent RChief Operating OfficerDec 16Sale18.692,50046,72519,326Dec 18 04:28 PM
BDTX Black Diamond Therapeutics, Inc. daily Stock Chart
BDTX [NASD]
Black Diamond Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own2.10% Shs Outstand35.93M Perf Week2.70%
Market Cap1.19B Forward P/E- EPS next Y-2.49 Insider Trans-49.44% Shs Float34.29M Perf Month2.17%
Income-54.50M PEG- EPS next Q-0.63 Inst Own94.90% Short Float8.78% Perf Quarter18.21%
Sales- P/S- EPS this Y-294.80% Inst Trans-3.07% Short Ratio13.68 Perf Half Y-14.39%
Book/sh9.11 P/B3.67 EPS next Y-22.10% ROA-17.90% Target Price49.25 Perf Year-
Cash/sh9.34 P/C3.58 EPS next 5Y- ROE-22.30% 52W Range17.63 - 46.25 Perf YTD-15.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.72% Beta-
Dividend %- Quick Ratio29.70 Sales past 5Y- Gross Margin- 52W Low89.62% ATR2.01
Employees32 Current Ratio29.70 Sales Q/Q- Oper. Margin- RSI (14)54.82 Volatility6.13% 6.21%
OptionableNo Debt/Eq0.00 EPS Q/Q-75.60% Profit Margin- Rel Volume0.88 Prev Close33.96
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume219.92K Price33.43
Recom1.60 SMA202.07% SMA505.32% SMA2002.92% Volume192,594 Change-1.56%
Nov-24-20Initiated Berenberg Buy $58
May-04-20Initiated H.C. Wainwright Buy $53
Feb-24-20Initiated JP Morgan Overweight $42
Feb-24-20Initiated Jefferies Buy
Feb-24-20Initiated Cowen Outperform
Feb-24-20Initiated Canaccord Genuity Buy $50
Nov-24-20 07:45AM  
Nov-20-20 07:45AM  
Nov-11-20 07:45AM  
Nov-10-20 07:45AM  
Oct-26-20 07:45AM  
Oct-12-20 07:45AM  
Oct-03-20 08:00AM  
Sep-29-20 07:45AM  
Sep-10-20 07:45AM  
Sep-08-20 04:05PM  
Aug-11-20 07:45AM  
Aug-10-20 08:42AM  
Aug-05-20 07:45AM  
Aug-04-20 07:45AM  
Jul-30-20 09:58AM  
Jul-28-20 07:45AM  
Jun-16-20 07:45AM  
May-27-20 07:45AM  
May-13-20 05:15PM  
May-12-20 07:45AM  
May-06-20 07:45AM  
May-05-20 11:46AM  
Feb-24-20 09:37AM  
Jan-30-20 04:29PM  
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bolzon Bradley J PhDDirectorNov 19Sale33.01130,0174,291,861968,954Nov 23 04:39 PM
Versant Venture Capital VI, L.10% OwnerNov 19Sale33.01114,8543,791,3314,818,600Nov 23 04:41 PM
Versant Venture Capital VI, L.10% OwnerNov 19Sale33.0115,163500,531968,954Nov 23 04:41 PM
Bolzon Bradley J PhDDirectorNov 18Sale33.0953617,738984,117Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 18Sale33.09632,085984,117Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 18Sale33.0947315,6534,933,454Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 17Sale33.0548916,161984,180Nov 19 09:19 PM
Versant Venture Capital VI, L.10% OwnerNov 17Sale33.053,705122,4504,933,927Nov 19 09:19 PM
Bolzon Bradley J PhDDirectorNov 17Sale33.054,194138,611984,180Nov 19 09:19 PM
Bolzon Bradley J PhDDirectorNov 16Sale33.012006,603984,669Nov 17 07:28 PM
Versant Venture Capital VI, L.10% OwnerNov 16Sale33.0123759984,669Nov 17 07:33 PM
Versant Venture Capital VI, L.10% OwnerNov 16Sale33.011775,8434,937,632Nov 17 07:33 PM
Versant Venture Capital VI, L.10% OwnerNov 13Sale33.7752517,731984,692Nov 17 07:33 PM
Versant Venture Capital VI, L.10% OwnerNov 13Sale33.773,975134,2534,937,809Nov 17 07:33 PM
Bolzon Bradley J PhDDirectorNov 13Sale33.774,500151,984984,692Nov 17 07:28 PM
Hatzis-Schoch BrentSee RemarksNov 12Option Exercise3.204,07813,0507,078Nov 13 04:25 PM
Versant Venture Capital VI, L.10% OwnerNov 12Sale34.151,81962,116985,217Nov 13 07:47 PM
Versant Venture Capital VI, L.10% OwnerNov 12Sale34.1513,779470,5264,941,784Nov 13 07:47 PM
Bolzon Bradley J PhDDirectorNov 12Sale34.1515,598532,642985,217Nov 13 07:46 PM
Hatzis-Schoch BrentSee RemarksNov 12Sale33.994,078138,6073,000Nov 13 04:25 PM
Roberts Christopher D.Chief Scientific OfficerNov 11Option Exercise10.865,00054,3005,000Nov 13 04:26 PM
Roberts Christopher D.Chief Scientific OfficerNov 11Sale34.905,000174,5000Nov 13 04:26 PM
Bolzon Bradley J PhDDirectorNov 11Sale34.7312,617438,217987,036Nov 12 05:38 PM
Versant Venture Capital VI, L.10% OwnerNov 11Sale34.731,47151,091987,036Nov 12 05:41 PM
Versant Venture Capital VI, L.10% OwnerNov 11Sale34.7311,146387,1275,646,377Nov 12 05:41 PM
Versant Venture Capital VI, L.10% OwnerNov 10Sale33.833,145106,381988,507Nov 12 05:41 PM
Versant Venture Capital VI, L.10% OwnerNov 10Sale33.8323,821805,7555,657,523Nov 12 05:41 PM
Bolzon Bradley J PhDDirectorNov 10Sale33.8326,966912,136988,507Nov 12 05:38 PM
Leggett ThomasChief Financial OfficerNov 09Option Exercise10.863,00032,5803,000Nov 12 05:00 PM
Leggett ThomasChief Financial OfficerNov 09Sale32.963,00098,8920Nov 12 05:00 PM
Versant Venture Capital VI, L.10% OwnerNov 09Sale33.0673524,296991,652Nov 10 07:24 PM
Bolzon Bradley J PhDDirectorNov 09Sale33.066,300208,250991,652Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 09Sale33.065,565183,9545,681,344Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 06Sale33.1336211,993992,387Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 06Sale33.132,73890,7065,686,909Nov 10 07:24 PM
Bolzon Bradley J PhDDirectorNov 06Sale33.133,100102,698992,387Nov 10 07:24 PM
Versant Venture Capital VI, L.10% OwnerNov 05Sale33.151,03234,208992,749Nov 06 04:44 PM
Versant Venture Capital VI, L.10% OwnerNov 05Sale33.157,816259,0795,689,647Nov 06 04:44 PM
Bolzon Bradley J PhDDirectorNov 05Sale33.158,848293,287992,749Nov 06 04:49 PM
Bolzon Bradley J PhDDirectorNov 04Sale33.142,50082,839993,781Nov 06 04:49 PM
Versant Venture Capital VI, L.10% OwnerNov 04Sale33.142929,676993,781Nov 06 04:44 PM
Versant Venture Capital VI, L.10% OwnerNov 04Sale33.142,20873,1645,697,463Nov 06 04:44 PM
Roberts Christopher D.Chief Scientific OfficerNov 03Option Exercise10.862,50027,1502,500Nov 04 08:37 PM
Roberts Christopher D.Chief Scientific OfficerNov 03Sale31.952,50079,8730Nov 04 08:37 PM
Epstein David M.See RemarksNov 02Option Exercise6.423,00019,260723,923Nov 03 07:56 PM
Epstein David M.See RemarksNov 02Sale31.1412,000373,656711,923Nov 03 07:56 PM
Versant Venture Capital VI, L.10% OwnerOct 27Sale33.03933,072994,073Oct 28 05:58 PM
Versant Venture Capital VI, L.10% OwnerOct 27Sale33.0370723,3545,699,671Oct 28 05:58 PM
Bolzon Bradley J PhDDirectorOct 27Sale33.0380026,426994,073Oct 28 05:51 PM
Bolzon Bradley J PhDDirectorOct 26Sale33.308,103269,867994,166Oct 28 05:51 PM
Versant Venture Capital VI, L.10% OwnerOct 26Sale33.3094531,473994,166Oct 28 05:58 PM
Versant Venture Capital VI, L.10% OwnerOct 26Sale33.307,158238,3945,700,378Oct 28 05:58 PM
Bolzon Bradley J PhDDirectorOct 19Sale33.434,233141,513995,111Oct 20 08:03 PM
Versant Venture Capital VI, L.10% OwnerOct 19Sale33.4349416,515995,111Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 19Sale33.433,739124,9985,707,536Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 16Sale33.571,01634,110995,605Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 16Sale33.577,697258,4105,711,275Oct 20 08:09 PM
Bolzon Bradley J PhDDirectorOct 16Sale33.578,713292,520995,605Oct 20 08:03 PM
Bolzon Bradley J PhDDirectorOct 15Sale33.032,80092,496996,621Oct 20 08:03 PM
Versant Venture Capital VI, L.10% OwnerOct 15Sale33.0332710,802996,621Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 15Sale33.032,47381,6945,718,972Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 14Sale33.0964221,244996,948Oct 15 07:22 PM
Versant Venture Capital VI, L.10% OwnerOct 14Sale33.094,859160,7875,721,445Oct 15 07:22 PM
Bolzon Bradley J PhDDirectorOct 14Sale33.095,501182,031996,948Oct 15 07:26 PM
Bolzon Bradley J PhDDirectorOct 13Sale33.3911,739391,984997,590Oct 15 07:26 PM
Versant Venture Capital VI, L.10% OwnerOct 13Sale33.391,36945,713997,590Oct 15 07:22 PM
Versant Venture Capital VI, L.10% OwnerOct 13Sale33.3910,370346,2715,726,304Oct 15 07:22 PM
Hatzis-Schoch BrentSee RemarksOct 12Option Exercise3.204,07813,0507,078Oct 14 04:32 PM
Versant Venture Capital VI, L.10% OwnerOct 12Sale33.11471,556998,959Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 12Sale33.1135311,6875,736,674Oct 13 07:41 PM
Hatzis-Schoch BrentSee RemarksOct 12Sale32.704,078133,3313,000Oct 14 04:32 PM
Bolzon Bradley J PhDDirectorOct 12Sale33.1140013,243998,959Oct 13 07:48 PM
Bolzon Bradley J PhDDirectorOct 09Sale33.673,800127,933999,006Oct 13 07:48 PM
Versant Venture Capital VI, L.10% OwnerOct 09Sale33.6744314,914999,006Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 09Sale33.673,357113,0185,737,027Oct 13 07:41 PM
Leggett ThomasChief Financial OfficerOct 08Option Exercise10.863,00032,5803,000Oct 09 04:12 PM
Versant Venture Capital VI, L.10% OwnerOct 08Sale33.472,14971,934999,449Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 08Sale33.4716,276544,8145,740,384Oct 13 07:41 PM
Bolzon Bradley J PhDDirectorOct 08Sale33.4718,425616,748999,449Oct 13 07:48 PM
Leggett ThomasChief Financial OfficerOct 08Sale33.533,000100,5760Oct 09 04:12 PM
Bolzon Bradley J PhDDirectorOct 07Sale33.5627,836934,0791,041,206Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 07Sale33.563,246108,9241,041,206Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 07Sale33.5624,590825,1545,756,660Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 06Sale33.262,11070,1761,044,452Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 06Sale33.2615,980531,4775,781,250Oct 08 07:14 PM
Bolzon Bradley J PhDDirectorOct 06Sale33.2618,090601,6541,044,452Oct 08 07:14 PM
Roberts Christopher D.Chief Scientific OfficerOct 05Option Exercise10.862,50027,1502,500Oct 07 04:27 PM
Roberts Christopher D.Chief Scientific OfficerOct 05Sale31.282,50078,1880Oct 07 04:27 PM
Epstein David M.See RemarksOct 01Option Exercise6.423,00019,260732,923Oct 02 05:07 PM
Epstein David M.See RemarksOct 01Sale30.3312,000363,962720,923Oct 02 05:07 PM
INGRAM ROBERT ALEXANDERDirectorSep 30Buy30.465,000152,2855,000Oct 01 04:06 PM
Leggett ThomasChief Financial OfficerSep 14Option Exercise10.863,00032,5803,000Sep 16 06:09 PM
Hatzis-Schoch BrentSee RemarksSep 14Option Exercise3.204,07813,0507,078Sep 16 06:11 PM
Hatzis-Schoch BrentSee RemarksSep 14Sale31.044,078126,5833,000Sep 16 06:11 PM
Leggett ThomasChief Financial OfficerSep 14Sale31.003,00093,0000Sep 16 06:09 PM
Roberts Christopher D.Chief Scientific OfficerSep 03Option Exercise10.862,50027,1502,500Sep 04 05:27 PM
Roberts Christopher D.Chief Scientific OfficerSep 03Sale29.592,50073,9870Sep 04 05:27 PM
Versant Venture Capital VI, L.10% OwnerAug 11Sale33.0888329,2111,125,778Aug 12 07:57 PM
Versant Venture Capital VI, L.10% OwnerAug 11Sale33.086,692221,3806,797,230Aug 12 07:57 PM
Bolzon Bradley J PhDDirectorAug 11Sale33.087,575250,5911,125,778Aug 12 07:46 PM
TARS Tarsus Pharmaceuticals, Inc. daily Stock Chart
TARS [NASD]
Tarsus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own18.00% Shs Outstand19.60M Perf Week-8.34%
Market Cap390.04M Forward P/E- EPS next Y-2.99 Insider Trans0.00% Shs Float12.46M Perf Month-1.46%
Income-7.30M PEG- EPS next Q-0.50 Inst Own49.92% Short Float1.08% Perf Quarter-
Sales- P/S- EPS this Y-254.10% Inst Trans- Short Ratio1.18 Perf Half Y-
Book/sh- P/B- EPS next Y-50.30% ROA- Target Price- Perf Year-
Cash/sh2.71 P/C7.35 EPS next 5Y- ROE- 52W Range15.32 - 27.90 Perf YTD-3.30%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-28.67% Beta-
Dividend %- Quick Ratio17.80 Sales past 5Y- Gross Margin- 52W Low29.85% ATR2.71
Employees12 Current Ratio17.80 Sales Q/Q- Oper. Margin- RSI (14)- Volatility9.93% 12.28%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.47 Prev Close20.82
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume113.82K Price19.90
Recom1.50 SMA20-12.45% SMA50-11.79% SMA200-11.79% Volume55,047 Change-4.42%
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
Nov-19-20 03:24PM  
Nov-13-20 07:35PM  
Oct-20-20 04:05PM  
Oct-16-20 06:05PM  
Oct-15-20 08:35PM  
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
ADPT Adaptive Biotechnologies Corporation daily Stock Chart
ADPT [NASD]
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-0.95 Insider Own1.30% Shs Outstand134.37M Perf Week-5.45%
Market Cap6.15B Forward P/E- EPS next Y-1.15 Insider Trans-82.56% Shs Float128.88M Perf Month-10.52%
Income-122.30M PEG- EPS next Q-0.29 Inst Own82.10% Short Float3.72% Perf Quarter12.11%
Sales92.40M P/S66.54 EPS this Y-42.00% Inst Trans9.59% Short Ratio5.58 Perf Half Y18.42%
Book/sh5.77 P/B7.94 EPS next Y-6.50% ROA-13.10% Target Price58.17 Perf Year62.81%
Cash/sh6.23 P/C7.36 EPS next 5Y2.20% ROE-20.10% 52W Range15.19 - 54.20 Perf YTD53.18%
Dividend- P/FCF- EPS past 5Y- ROI-12.90% 52W High-15.44% Beta-
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin75.90% 52W Low201.71% ATR2.83
Employees453 Current Ratio8.70 Sales Q/Q0.80% Oper. Margin- RSI (14)45.32 Volatility5.17% 6.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-143.60% Profit Margin- Rel Volume0.40 Prev Close45.01
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume859.80K Price45.83
Recom1.60 SMA20-4.90% SMA50-5.92% SMA20017.52% Volume341,748 Change1.82%
Oct-08-20Resumed BTIG Research Buy $60
Sep-09-20Initiated Morgan Stanley Equal-Weight $42
Jun-03-20Initiated Goldman Buy $60
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Nov-23-20 08:00AM  
Nov-19-20 06:32AM  
Nov-13-20 08:00AM  
Nov-11-20 05:21AM  
05:00AM  
Nov-10-20 05:25PM  
05:22PM  
04:13PM  
04:10PM  
Nov-03-20 12:30PM  
Oct-28-20 05:30PM  
Oct-13-20 04:05PM  
Sep-28-20 10:52AM  
Sep-01-20 04:03PM  
Aug-11-20 01:01AM  
Aug-10-20 06:35PM  
04:05PM  
12:44PM  
08:05AM  
Aug-06-20 09:24AM  
Aug-04-20 09:30AM  
Jul-30-20 06:19AM  
Jul-28-20 06:04PM  
Jul-16-20 12:00PM  
Jul-15-20 07:47PM  
Jul-14-20 04:44PM  
Jul-09-20 04:29PM  
08:05AM  
Jun-23-20 11:54AM  
Jun-17-20 08:56AM  
Jun-15-20 10:27AM  
Jun-11-20 09:00AM  
Jun-08-20 04:03PM  
Jun-07-20 06:25AM  
May-27-20 04:03PM  
May-19-20 08:03AM  
May-18-20 02:47PM  
May-14-20 11:51AM  
May-13-20 12:31PM  
07:02AM  
May-12-20 04:03PM  
08:06AM  
May-11-20 10:57AM  
09:57AM  
May-08-20 09:09AM  
May-06-20 03:06PM  
02:50PM  
12:10PM  
08:19AM  
08:00AM  
May-05-20 12:00PM  
Apr-30-20 08:51AM  
06:39AM  
Apr-27-20 04:03PM  
Apr-20-20 08:15AM  
Apr-17-20 09:13PM  
12:40PM  
Apr-15-20 04:47PM  
08:26AM  
Apr-09-20 07:45PM  
Apr-07-20 08:35PM  
Apr-05-20 10:14AM  
Apr-03-20 10:51AM  
Apr-02-20 07:58PM  
05:50PM  
04:23PM  
04:04PM  
12:29PM  
09:34AM  
09:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:45PM  
Mar-23-20 11:06AM  
Mar-20-20 02:00PM  
01:02PM  
Feb-29-20 07:12AM  
Feb-27-20 05:54PM  
Feb-26-20 04:05PM  
Feb-21-20 10:20AM  
Feb-19-20 04:05PM  
Feb-12-20 04:05PM  
Feb-10-20 08:44AM  
Feb-03-20 11:27AM  
Jan-31-20 11:52AM  
Jan-29-20 09:50AM  
Jan-23-20 08:53PM  
Jan-22-20 08:25AM  
Jan-21-20 04:39PM  
04:02PM  
Jan-13-20 07:30AM  
Jan-08-20 07:30AM  
Dec-30-19 04:05PM  
10:04AM  
Dec-26-19 02:47PM  
Dec-20-19 04:17PM  
Dec-16-19 09:24PM  
Dec-13-19 04:52AM  
Dec-09-19 08:44AM  
08:00AM  
Dec-04-19 04:30PM  
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taylor Stacy LSVP and General CounselNov 23Option Exercise7.032,88020,2504,180Nov 24 08:00 PM
Taylor Stacy LSVP and General CounselNov 23Sale46.312,880133,3591,300Nov 24 08:00 PM
ROBINS CHAD MCEO and ChairmanNov 19Option Exercise0.3316,6805,5041,794,860